Alnylam Announces Second Annual Advocacy for Impact Grants Program
20 November 2019 - 12:00AM
Business Wire
− Program Aims to Inspire Creative Patient
Advocacy Solutions to Unique Challenges in Rare Disease Communities
−
− Funding Will Support Unmet Needs in the ATTR
Amyloidosis, Acute Hepatic Porphyria and Primary Hyperoxaluria Type
1 Communities –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it is accepting
applications for its second annual global competitive grants
program, Advocacy for Impact. This program aims to provide patient
advocacy groups around the world with the flexibility to address
the critical unmet needs of the diverse rare disease communities
they serve.
“We were strongly encouraged by the number of applicants we
received in the first year of the Advocacy for Impact grants
program,” said Tiffany Patrick, Head of Global Patient Advocacy and
Engagement at Alnylam. “The output from last year’s program has
been impressive, and we are thrilled to continue into our second
year. We look forward to seeing the creativity that advocacy groups
bring to their work on behalf of patients and families around the
world facing these rare diseases.”
Advocacy for Impact grants will recognize and fund new projects,
each in an amount up to $50,000, that focus on serving the unmet
needs of ATTR amyloidosis, acute hepatic porphyria and/or primary
hyperoxaluria type 1 patients, specifically those that:
- Increase disease awareness and access to diagnosis
- Offer education to patients, families, caregivers, healthcare
providers, and/or the public
- Improve patient care
To be eligible, patient advocacy groups must have charitable
status and may only submit one proposal per year. Applications will
be accepted via email to AdvocacyForImpact@alnylam.com from today
through January 3, 2020. Eligible patient advocacy groups may
submit their applications in any language. A committee of experts
from within and outside of Alnylam will review each application
independently. Recipients will be announced in mid-2020.
In its first year of the program, Alnylam provided $248,000 in
funding to seven patient groups in six countries. One of the grant
recipients, the British Porphyria Association, just recently
organized the largest porphyria event to date in the UK related to
mental health and well-being.
“We held an immersive and engaging event that brought together
all of those connected to the porphyrias, especially those under 30
years of age, who are often socially alienated by their condition,”
said Liz Gill, Vice Chair, British Porphyria Association. “This
truly would not have been possible without Alnylam’s Advocacy for
Impact grant!”
Additional information about these recipients and their programs
can be read here. Please visit the Alnylam Advocacy for Impact
grants page for additional information about the application
process.
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare genetic, cardio-metabolic,
hepatic infectious, and central nervous system (CNS)/ocular
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn
scientific possibility into reality, with a robust discovery
platform. Alnylam’s first commercial RNAi therapeutic is ONPATTRO®
(patisiran), approved in the U.S., EU, Canada, Switzerland and
Japan. Alnylam has a deep pipeline of investigational medicines,
including five product candidates that are in late-stage
development. Looking forward, Alnylam will continue to execute on
its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam employs
over 1,200 people worldwide and is headquartered in Cambridge, MA.
For more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam or
on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191119005112/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024